Table 2 Primary and secondary outcomes in the study
From: Induced hypernatremia in patients with moderate-to-severe ARDS: a randomized controlled study
Hypertonic saline (n = 20) | Control (n = 20) | p value | Effect size | |
|---|---|---|---|---|
Primary outcome | ||||
Extubated or with ≥ 1-point reduction in LIS by day 7 | 15 (75%) | 7 (35%) | 0.02 | 5.6 (1.4 to 21.8) |
Extubated by day 7 | 12 (60%) | 6 (30%) | 0.11 | 3.5 (0.9 to 12.9) |
≥1-point reduction in LIS by day 7 | 14 (70%) | 7 (35%) | 0.06 | 4.3 (1.1 to 16.3) |
Secondary outcomes | ||||
LIS at day 7a | 1.8 (1.0–2.9) | 2.8 (2.2–3.2) | 0.11 | 0.9 (− 1.8 to 0.3) |
VFD28a | 23 (17–24) | 18 (18–24) | 0.10 | 3.7 (− 1.7 to 9.2) |
LOMV (hours)a | 133 (97–260) | 336 (154–432) | 0.04 | − 112 (− 249 to − 10) |
RRT (n,%) | 7 (35%) | 5 (25%) | 0.73 | 1.6 (0.4 to 6.3) |
Diuretics (n,%) | 15 (75%) | 17 (65%) | 0.69 | 0.5 (0.1 to 2.6) |
Inhaled NO (n,%) | 11 (55%) | 12 (60%) | 1.00 | 0.8 (0.2 to 2.8) |
ICU LOS (day)a | 12.0 (6.6–16.7) | 19.7 (9.9–37.6) | 0.06 | − 9.2 (− 18.7 to 0.3) |
Hospital LOS (day)a | 19.0 (13.6–26.8) | 46.4 (32.9–54.1) | 0.001 | − 24.4 (− 37.5 to − 11.2) |
Hospital mortality | 3/20 (15%) | 4/20 (20%) | 1.00 | 0.7 (0.1 to 3.6) |